the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI After the PTCA Surgery.

A Randomized, Double-blind, Placebo-controlled, Multi-center Clinical Trial of the Effect of Danhong Injection on Microcirculation in the Treatment of Patients With STEMI(ST- Elevation Myocardical Infarction) After the PTCA Surgery.

This study focused on the effect of Danhong injection on microcirculation in the treatment of patients with STEMI(ST-elevation myocardical infarction) after the PTCA surgery.

Research Topic.

• A randomized, double-blind, placebo-controlled, multi-center clinical trial of the effect of Danhong Injection on microcirculation in the treatment of patients with STEMI(ST- elevation myocardical infarction) after the PTCA surgery.

Research Purpose.

• This study focused on the effect of Danhong injection on microcirculation in the treatment of patients with STEMI(ST-elevation myocardical infarction) after the PTCA surgery.

Research design.

• A randomized, double-blind, placebo-controlled, multi-center clinical trial.

Inclusion Criteria:

• Clinically definite or laboratory-supported diagnosis of STEMI ,with the indication of PTCA surgery.
• 18≤Age≤75;
• Agreed to join in the study and signed the inform consent form.

Exclusion Criteria:

• Cardiogenic shock , Killip III-IV degree , papillary muscle rupture , septal perforation , episodes of ventricular tachycardia and ventricular fibrillation after electrical cardioversion , temporary pacemaker implanted AVB III degree.
• Past history of PCI and CABG
• Acute or chronic infectious diseases(for example severe pneumonia);
• Recent history of hemorrhagic stroke(within six months)
• Combined with liver and kidney dysfunction;
• History of valvular heart disease;
• Congenital heart disease or Pulmonary hypertension;
• All kinds of history of cardiomyopathy;
• Bleeding and other thrombotic diseases;
• Severe anemia , thrombocytopenia , Other diseases of the blood system;
• Cancer , Autoimmune disease , All kinds of the patients who use the glucocorticoid and immunosuppressor;
• Menstrual period women, pregnant women and lactating women, pregnancy test positive or recent family planning.